(Q39693553)

English

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study

scientific article published on 25 October 2011

In more languages
default for all languages
No label defined

No description defined

Statements

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit